Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Synergistic bacterial compositions and methods of manufacture and use thereof

A technology of composition and bacteria, applied in bacteria, drug combination, medical raw materials derived from bacteria, etc., can solve problems such as non-standardization and difficulty in large-scale implementation

Active Publication Date: 2022-04-08
SERES HEALTH
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, fecal transplantation is generally reserved for recurrent cases because of the potential for transmission of infectious or allergenic agents between hosts, the potential transfer of hundreds of unknown strains from donors to patients, and the difficulty of large-scale implement
Additionally, fecal transplants are nonstandard in nature and may deliver different desired and / or non-desired materials in any given donation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Synergistic bacterial compositions and methods of manufacture and use thereof
  • Synergistic bacterial compositions and methods of manufacture and use thereof
  • Synergistic bacterial compositions and methods of manufacture and use thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0244] Example 1. Construction of binary pairs in a high-throughput 96-well format / plate preparation

[0245] Bacterial pairs were used to identify binary pairs suitable for inhibiting C. difficile. To prepare plates for the high-yield screening assay of binary pairs, vials of the -80°C glycerol stock bacterial library were thawed and diluted to 1e8 CFU / mL. Each strain was then diluted 10X (to achieve a final concentration of 1e7 CFU / mL for each strain) into 200 μL of PBS + 15% glycerol in a well of a 96-well culture plate. Plates were then frozen at -80°C. When required, when tested with C. difficile in the CivSim assay, plates were removed from -80°C and thawed anaerobically at room temperature.

example 2

[0246] Example 2. Construction of triplets in a high-throughput 96-well format

[0247] Triple combinations of bacteria were used to identify triple combinations useful for inhibiting C. difficile. To prepare plates for high-yield screening triplet combinations, vials of the -80°C glycerol stock bacterial library were thawed and diluted to 1e8 CFU / mL. Each strain was then diluted 10X (to achieve a final concentration of 1e7 CFU / mL for each strain) into 200 μL of PBS + 15% glycerol in a well of a 96-well plate. Plates were then frozen at -80°C. When assay required, plates were removed from -80°C and thawed anaerobically at room temperature when tested with C. difficile in the CivSim assay.

example 3

[0248] Example 3. Construction of a CivSim analysis for screening bacterial compositions that inhibit the growth of Clostridium difficile

[0249] Compositions that inhibit the growth of C. difficile were identified using a competition assay (CivSim assay). Briefly, overnight cultures of C. difficile were grown in SweetB-FosIn under anaerobic conditions to allow C. difficile to grow. In some cases, other suitable media can be used. SweetB-FosIn is a version of BHI (Remel R452472) supplemented with the following components: Components per liter: 37g BHI powder (Remel R452472), supplemented with 5g yeast extract UF (Difco210929), 1g cysteine-HCl ( Spectrum C1473), 1g cellobiose (Sigma C7252), 1g maltose (Spectrum MA155), 1.5ml hematin solution, 1g soluble starch (Sigma-Aldrich S9765), 1g fructooligosaccharide / inulin (Jarrow Formulas 103025) and 50 mL 1M MOPS / KOH pH 7. To prepare the hematin solution, hematin (Sigma 51280) was dissolved in 0.1 M NaOH to make a 10 mg / mL stock. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides therapeutic compositions comprising microbial populations for the prevention, treatment and alleviation of symptoms associated with dysbiosis in mammalian subjects, such as humans.

Description

[0001] Related applications [0002] This application is related to commonly owned International Application No. PCT / US 13 / 2013, entitled "SYNERGISTIC BACTERIAL COMPOSITIONS AND METHODS OF PRODUCTION AND USETHEREOF", filed on November 25, 2013 71758, which both claim U.S. Provisional Patent Application No. 61 / 729,518, filed Nov. 23, 2012, U.S. Provisional Patent Application No. 61 / 729,519, filed Nov. 23, 2012, Nov. 23, 2012 Pending U.S. Provisional Patent Application No. 61 / 729,520, U.S. Provisional Patent Application No. 61 / 729,521, filed November 23, 2012, U.S. Provisional Patent Application No. 61 / 729,522, filed November 23, 2012 , U.S. Provisional Patent Application No. 61 / 729,524 filed on November 23, 2012, U.S. Provisional Patent Application No. 61 / 729,515 filed on November 23, 2012, and U.S. Provisional Patent Application No. 61 / 729,515 filed on November 23, 2012 Application No. 61 / 729,517, U.S. Provisional Patent Application No. 61 / 729,525, filed November 23, 2012, U.S...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K35/742A61K35/744A61K35/745A61K35/00
CPCA61K35/74A61K2035/11A61K2035/115C12N1/20A23L33/135A61P1/04A61P1/14Y02A50/30A61K45/06A61K35/742A61P1/00
Inventor M·R·赫恩K·D·利特科夫斯基A·M·德奥诺弗里奥T·K·奥苏米M-J·L·麦肯齐G·冯马尔扎恩D·N·库克D·A·贝利N·B·阿菲延J·G·奥宁斯
Owner SERES HEALTH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com